What should be the eGFR decline thresholds on kidney endpoints?

We have read with great interest the article by Heerspink et al.1 regarding the effects of newer kidney protective agents on renal endpoints. The authors analyze whether differences were present in the estimated glomerular filtration rate (eGFR) decline thresholds used in the studies that evaluated renal outcomes in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD), Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD), and the Study of Diabetic Nephropathy with Atrasentan (SONAR) trials.